Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries DOI Open Access
Fabrizio Bert, Giacomo Scaioli,

Lorenzo Vola

et al.

International Journal of Environmental Research and Public Health, Journal Year: 2022, Volume and Issue: 19(12), P. 7233 - 7233

Published: June 13, 2022

The need for an anti-COVID-19 booster dose posed organizational challenge health policy makers worldwide. Therefore, this study aimed to explore the policies regarding through overview of recommendations issued in high-income countries. Between 10 November and 16 December 2021, authors searched state-level official documents about offer dose, considering 43 countries belonging European Union (EU) or Organisation Economic Co-operation Development (OECD). Mainly due lack English translation, 15 were excluded. A total 135 selected. Almost all started administering between September 2021. most used products mRNA vaccines, followed by Vaxzevria-AstraZeneca Jcovden-Janssen/Johnson & Johnson. All established criteria define categories individuals be vaccinated as a priority. six/five-months interval was main choice general population with while shorter intervals chosen vulnerable other vaccines. Despite diversities related differences systems, economical resources, numbers, adapt these factors massive vaccination campaign, progressive convergence towards same highlighted.

Language: Английский

A Systematic Review of Predictor Composition, Outcomes, Risk of Bias, and Validation of COVID-19 Prognostic Scores DOI Creative Commons
Katharina S. Appel, Ramsia Geisler, Daniel Maier

et al.

Clinical Infectious Diseases, Journal Year: 2023, Volume and Issue: 78(4), P. 889 - 899

Published: Oct. 25, 2023

Abstract Background Numerous prognostic scores have been published to support risk stratification for patients with coronavirus disease 2019 (COVID-19). Methods We performed a systematic review identify the confirmed or clinically assumed COVID-19 cases. An in-depth assessment and of bias (ROB) analysis (Prediction model Risk Of Bias ASsessment Tool [PROBAST]) was conducted fulfilling predefined criteria ([I] area under curve [AUC)] ≥ 0.75; [II] separate validation cohort present; [III] training data from multicenter setting [≥2 centers]; [IV] point-scale scoring system). Results Out 1522 studies extracted MEDLINE/Web Science (20/02/2023), we identified 242 outcome prognosis (mortality 109, severity 116, hospitalization 14, long-term sequelae 3). Most were developed using retrospective (75.2%) single-center (57.1%) cohorts. Predictor revealed primary use laboratory sociodemographic information in mortality scores. Forty-nine included analysis. The results indicated heterogeneous quality predictor selection, only five featuring low ROB. Among those, based on number heterogeneity studies, 4C Mortality Score can be recommended clinical application so far. Conclusions translation most existing COVID appear unreliable. Guided development selection would improved generalizability may enhance pandemic preparedness future.

Language: Английский

Citations

8

Indole-3-carbinol in vitro antiviral activity against SARS-Cov-2 virus and in vivo toxicity DOI Creative Commons
Federica Centofanti, Tonino Alonzi, Andrea Latini

et al.

Cell Death Discovery, Journal Year: 2022, Volume and Issue: 8(1)

Published: Dec. 15, 2022

The effects of indole-3-carbinol (I3C) compound have been described deeply as antitumor drug in multiple cancers. Herein, I3C was tested for toxicity and antiviral activity against SARS-CoV-2 infection. Antiviral assessed vitro both VeroE6 cell line human Lung Organoids (hLORGs) where exhibited a direct anti-SARS-CoV-2 replication with an effect modulation the expression genes implicated innate immunity inflammatory response observed at 16.67 μM. Importantly, we further show is also effective Omicron variant. In mouse model, instead, possible through two different routes administration: intragastrically (i.g.) intraperitoneally (i.p.). LD50 (lethal dose 50%) values mice were estimated to be: 1410 1759 mg/kg i.g.; while i.p. administration were: 444.5 375 male female mice, respectively. Below these values, (in particular 550 i.g. 250 i.p.) induces neither death, nor abnormal toxic symptoms well no histopathological lesions tissues analysed. These tolerated doses are much higher than those already proven pre-clinical cancer models experiments. conclusion, exhibits significant activity, recorded this indicated doses, characterizing it safe potential compound. results presented study could provide experimental data necessary start clinical trials treatment beyond.

Language: Английский

Citations

13

Usability of telehealth among healthcare providers during COVID-19 pandemic in Nineveh Governorate, Iraq DOI Creative Commons
Hala F. Kasim, Amina İbrahim Salih, Farah Mwafaq Attash

et al.

Public Health in Practice, Journal Year: 2023, Volume and Issue: 5, P. 100368 - 100368

Published: Feb. 10, 2023

To identify the usability of telehealth services and barriers during coronavirus disease (COVID-19) pandemic among healthcare providers in Nineveh Governorate-Iraq. This was a multicenter cross-sectional survey. We collected required data from April to July 2022 using self-administered open-ended questionnaires. The were physicians, pharmacists, nurses with at least six months hospitals. A modified form Telehealth Usability Questionnaire (TUQ) used assess services. There 460 providers, which 269/460 (58.5%) users These mostly physicians (n = 167/269, 62.1%), (52/269, 19.3%), pharmacists 50/269, 18.6%), p-value 0.001. During COVID-19 pandemic, 100/167, 60.0%) 28/50, 56.0%) increased their provision Approximately 60% preferred provide synchronized manner. participants smartphones through Messenger/Facebook WhatsApp applications, specifically utilizing voice and/or video messages. some agreement 269) regarding overall mean score (±SD) 4.8 (±0.88). most reported poor Internet services, presence specific diseases, lack technical comprehension, insufficient time allocated service. Healthcare demonstrated tendency towards Despite available barriers, triage collaborations patients, institutions are needed achieve more successful adoption these

Language: Английский

Citations

7

Telemedicine in Vascular Surgery During COVID-19 Pandemic: A Systematic Review and Narrative Synthesis DOI Open Access
Shu Ning Yew, Bo Yuan Khor,

Eleanor Wong

et al.

Annals of Vascular Surgery, Journal Year: 2023, Volume and Issue: 93, P. 166 - 173

Published: April 1, 2023

Language: Английский

Citations

7

Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries DOI Open Access
Fabrizio Bert, Giacomo Scaioli,

Lorenzo Vola

et al.

International Journal of Environmental Research and Public Health, Journal Year: 2022, Volume and Issue: 19(12), P. 7233 - 7233

Published: June 13, 2022

The need for an anti-COVID-19 booster dose posed organizational challenge health policy makers worldwide. Therefore, this study aimed to explore the policies regarding through overview of recommendations issued in high-income countries. Between 10 November and 16 December 2021, authors searched state-level official documents about offer dose, considering 43 countries belonging European Union (EU) or Organisation Economic Co-operation Development (OECD). Mainly due lack English translation, 15 were excluded. A total 135 selected. Almost all started administering between September 2021. most used products mRNA vaccines, followed by Vaxzevria-AstraZeneca Jcovden-Janssen/Johnson & Johnson. All established criteria define categories individuals be vaccinated as a priority. six/five-months interval was main choice general population with while shorter intervals chosen vulnerable other vaccines. Despite diversities related differences systems, economical resources, numbers, adapt these factors massive vaccination campaign, progressive convergence towards same highlighted.

Language: Английский

Citations

12